BCAR1 Rabbit Polyclonal Antibody

CAT#: TA325258S

Rabbit Polyclonal p130 Cas (Tyr410) Antibody (Phospho-specific)

Size: 30 ul 100 ul



Need it in bulk or conjugated?
Get a free quote

CNY 1,470.00


货期*
5 工作日

规格
    • 30 ul

Product images

经常一起买 (3)
beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00


Recombinant protein of human breast cancer anti-estrogen resistance 1 (BCAR1), 20 µg
    • 20 ug

CNY 2,900.00
CNY 6,650.00


Transient overexpression lysate of breast cancer anti-estrogen resistance 1 (BCAR1), transcript variant 6
    • 100 ug

CNY 3,080.00

Specifications

Product Data
Applications WB
Recommend Dilution WB: 1:500-1:2000; IHC: 1:50-1:200
Reactivity Human, Mouse, Rat
Modifications Phospho-specific
Host Rabbit
Clonality Polyclonal
Immunogen The antiserum was produced against A synthesized peptide derived from human p130 Cas around the phosphorylation site of Tyrosine 410
Formulation Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Concentration lot specific
Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific peptide.
Conjugation Unconjugated
Storage Condition Store at -20°C as received.
Predicted Protein Size 130 kDa
Gene Name BCAR1, Cas family scaffolding protein
Background a docking protein containing multiple protein-protein interaction domains. Plays a central coordinating role for tyrosine-kinase-based signaling related to cell adhesion. Implicated in induction of cell migration.
Synonyms CAS; CAS1; CASS1; CRKAS; P130Cas
Reference Data
Protein Families Druggable Genome
Protein Pathways Chemokine signaling pathway, Focal adhesion, Leukocyte transendothelial migration, Regulation of actin cytoskeleton
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...